Amgen

Open: 263.15 Close: 267.47 Change: 4.32

5 things an AI found about Amgen Stock that you should know before investing.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen agreed to buy Horizon Theraputics for about a year. FDA voted against Amgen request for full approval of G12C KRAS inhibitor. FTC Agreement Clears Amgen to Proceed with $27.8B Horizon Deal. Amgen CEO Bob Bradways was interviewed by @Bloomberg TV. Amgen is excited to announce the first approval of the first treatment specifically designed specifically for patients with KRAS GAS.

Today's News

Amgen Biotech Experience program expands to reach more than 180,000 additional students over next two years. This latest expansion is made possible by additional funding of $12.4 million from the Amgen Foundation. Amgen completes $27.8B acquisition of Horizon Therapeutics. Amgen agreed to buy Horizon Theraputics for about a year. Amgen completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash. FDA voted against Amgen request for full approval of G12C KRAS inhibitor. FTC Agreement Clears Amgen to Proceed with $27.8B Horizon Deal 9/1/2023 Under a consent order agreement announced Friday, Amgen is prohibited from bundling any of its products with Horizons Tepezza or Krystexxa. FTC Temporarily Withdraws Challenge to $27B Amgen-Horizon Deal. Amgen completes acquisition of horizon therapeutics plc. amgen completes. acquisition of Horizon Therapeutics plca. Amgen completes acquisition of Horizon Therapeutics plc for $116.50 per share in cash. Amgen expects to provide updated FY 2023 guidance during its third quarter earnings call. Amgen completes acquisition of Horizon Therapeutics plc. Pentwater Capital Management, HBK Investments and Farallon Capital Management are reaping a windfall from bets that US regulators wouldnt be able to stop Amgen. Amgen completes acquisition of Horizon Therapeutics plc. Amgen announced that it has completed its acquisition of $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion. Amgen completes acquisition of Horizon Therapeutics plc. Amgen completed its acquisition for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion. Amgen completes its acquisition of Horizon Therapeutics plc for $116.50 per share in cash. Amgen expects to provide updated FY 2023 guidance during its third quarter earnings call. Amgen Completes Purchase of Horizon Therapeutics. Amgen revealed in a company press release that it has officially finished its purchase of Horizon. Amgen completes $27.8 billion acquisition of Horizon Therapeutics. US-based Amgen won out in a three-way tussle with Sanofi. Amgens late-stage confirmatory study may not be considered adequate and well-controlled FDA staff reviewers cited several issues with the way the study was conducted. Shares of Amgen fell nearly 2% to $261. Amgen recognizes #AAPIHeritageMonth in the workplace and society. Amgen is excited to announce the first approval of the first treatment specifically designed specifically for patients with KRAS GAS. Amgen announces @US_FDA approval of the first biologic for #severeasthma in the U.S. Amgen employees have given back in numerous ways to the communities where they live and work during the last few months. Amgen is an ally and will continue to fight for equal justice and equal opportunity for all. 50-60% of the water is reused at Amgens largest biomanufacturing facility in Puerto Rico.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Horizon, acquisition, complete, Therapeutics, plc, share, and the most common words in the summary are: amgen, news, horizon, best, bloomberg, drug, job, . One of the sentences in the summary was: FDA voted against Amgen request for full approval of G12C KRAS inhibitor. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #news #horizon #best #bloomberg #drug #job.